iifl-logo-icon 1

Astrazeneca Pharma India Ltd Cash Flow Statement

6,624.1
(-0.62%)
Dec 5, 2024|03:31:08 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Astrazeneca Phar FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

83.04

127.09

113.97

43.8

Depreciation

-16.95

-20.13

-18.58

-14.74

Tax paid

-21.44

-33.79

-41.76

-17.89

Working capital

57.86

101.15

103.65

52.76

Other operating items

Operating

102.51

174.32

157.28

63.93

Capital expenditure

9.05

26.94

26.99

3.28

Free cash flow

111.56

201.26

184.27

67.21

Equity raised

900.96

722.31

531.66

433.89

Investing

0

0

0

0

Financing

20.77

23.98

11.84

0

Dividends paid

5

5

2.5

0

Net in cash

1,038.29

952.55

730.27

501.1

Astrazeneca Phar : related Articles

AstraZeneca Pharma India Gets CDSCO Nod for Lynparza Cancer Drug
26 Nov 2024|11:42 PM

It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.

Read More
AstraZeneca to introduce COPD inhaler Breztri Aerosphere in India
19 Nov 2024|09:50 AM

This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.

Read More
AstraZeneca India Posts 31% Revenue Surge in Q2
14 Nov 2024|10:48 AM

For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments.

Read More
AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
24 Sep 2024|06:20 PM

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.

Read More
AstraZeneca Pharma gets approval to launch cancer drug in India
24 Sep 2024|10:54 AM

The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.

Read More
Top 10 stocks for today - 24th September 2024
24 Sep 2024|09:00 AM

Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.

Read More
Cancer Patients Benefit as GST on Medications Slashed
10 Sep 2024|12:22 PM

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp